Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.

Abstract

This case describes the challenges that Dr Reddy's Laboratories, the second largest pharmaceutical company in India in 2009, faced in making its vision (of becoming the first discovery-led global pharmaceutical company from India - 'the Merck or Pfizer of India') a reality. The company had grown from its very humble beginnings to become a USD1.4 billion multinational in the space of 25 short years. Dr Reddy's early success was based on unbranded and branded generics. The company had a global presence and India revenues represented only 16% of the total. Dr Reddy's had built a world class manufacturing organisation and was also expert at mounting patent challenges. Through a series of acquisitions, the company had assembled a high quality global supply chain. As the generics opportunity began to plateau, Dr Reddy's has recently sought to develop its skills in new drug discovery and marketing. The company has launched four new growth businesses: (1) the polypill project that seeks to combine proven generics in a single pill to provide more effective and low cost treatments for chronic diseases like cardiovascular disease (CVD), depression and osteoarthritis; (2) a specialty dermatology business in the US; (3) high-margin (and high-risk) drug discovery, with five new chemical entities in the pipeline as of 2009; and (4) biologics, an exciting and fast-growing segment of the pharmaceuticals industry. The challenge for the student is to analyse how these dots are connected and whether these initiatives are sufficient for the company to realise its ambitious vision. The case also discusses how the company's CEO, GV Prasad, has restructured the organisation to help realise its vision and has sought to attract and retain the new kind of talent that would be needed in this effort.
Location:
Industry:
Size:
USD1.4 billion in 2009 revenues
Other setting(s):
2003-2009

About

Abstract

This case describes the challenges that Dr Reddy's Laboratories, the second largest pharmaceutical company in India in 2009, faced in making its vision (of becoming the first discovery-led global pharmaceutical company from India - 'the Merck or Pfizer of India') a reality. The company had grown from its very humble beginnings to become a USD1.4 billion multinational in the space of 25 short years. Dr Reddy's early success was based on unbranded and branded generics. The company had a global presence and India revenues represented only 16% of the total. Dr Reddy's had built a world class manufacturing organisation and was also expert at mounting patent challenges. Through a series of acquisitions, the company had assembled a high quality global supply chain. As the generics opportunity began to plateau, Dr Reddy's has recently sought to develop its skills in new drug discovery and marketing. The company has launched four new growth businesses: (1) the polypill project that seeks to combine proven generics in a single pill to provide more effective and low cost treatments for chronic diseases like cardiovascular disease (CVD), depression and osteoarthritis; (2) a specialty dermatology business in the US; (3) high-margin (and high-risk) drug discovery, with five new chemical entities in the pipeline as of 2009; and (4) biologics, an exciting and fast-growing segment of the pharmaceuticals industry. The challenge for the student is to analyse how these dots are connected and whether these initiatives are sufficient for the company to realise its ambitious vision. The case also discusses how the company's CEO, GV Prasad, has restructured the organisation to help realise its vision and has sought to attract and retain the new kind of talent that would be needed in this effort.

Settings

Location:
Industry:
Size:
USD1.4 billion in 2009 revenues
Other setting(s):
2003-2009

Related